Dr. Chandra Belani is the Chief Science Officer of the IASLC. He directs the IASLC's scientific strategy, including research projects, publications, educational content for conferences. Dr. Belani also serves as a spokesperson for the IASLC at conferences, with the media and in meetings with partners and the community. Dr. Belani is also currently a Professor of Medicine in the Division of Hematology/Oncology in the Department of Medicine at the Penn State Hershey Medical Center and College of Medicine in Hershey, PA. He is a lung cancer expert and a recognized thought leader.

IASLC President, Dr. Tetsuya Mitsudomi, is a Professor of Thoracic Surgery at Kindai University Faculty of Medicine, Osaka-Sayama, Japan.  

Recipient of many prestigious awards, his current research interests include precision treatment of lung cancer based on cancer genotypes such as EGFR mutations or ALK translocations. He has published more than 400 papers in international peer-reviewed journals. 

Prof. Yi-Long Wu is a tenured professor of Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung Cancer Institute. He is the Past President of Chinese Society of Clinical Oncology (CSCO), the President of Chinese Thoracic Oncology Group(C-TONG). , He served as a Member of Board of Directors of the International Association Study of Lung Cancer(IASLC) from 2013-2017 and a past Member of staging committee of the IASLC (2009-2017). . .  

He graduated from Sun Yat-sen University of Medical Sciences in 1982, and completed his thoracic surgery training in Germany in 1989. His main research interests are the multidisciplinary synthetic therapy on lung cancer in translation medicine and evidence-based medicine in oncology. He is leading the Chinese lung cancer research field and has been the Principal Investigator or Co-PI of more than 120 international or national multicenter clinical trials. He has contributed 20 books on cancer and has published more than 300 articles in peer-reviewed journals including J Clin Oncol, Lancet Oncol, New Engl J Med，Cancel Cell and J Thorac Oncol. He also serves on the editorial boards of Nature Review Clinical Oncology, Lung Cancer, Annals of Surgical Oncology.

Ross Soo is a Senior Consultant at the Department of Haematology-Oncology, National University Cancer Institute, Singapore.

He received his MB, BS from Monash University, Melbourne, underwent specialist training in Melbourne and Sydney and subsequently became a Fellow of the Royal Australasian College of Physicians and the Academy of Medicine, Singapore and obtained a PhD from University of Western Australia. He leads the Lung Tumor Group at the National University Cancer Institute, Singapore. His research interests are in lung cancer, early drug development and biomarkers.

His professional affiliations include memberships of the European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the Singapore Society of Oncology (SSO). He is currently an Associate Editor for Lung Cancer and sits on various committees including NUHS Tissue Repository Domain Specific Scientific Review Working Committee (Domain D), Long-term International Fellowship (LIFe) Subcommittee of the Grant Selection Committee of the Conquer Cancer Foundation of ASCO, IASLC Communications Committee. He is currently Chair of the National Healthcare Group Domain-Specific Ethics Review Board and co-President for IASLC WCLC 2020, and was past Chair of the IASLC Communications Committee.

Nevan Krogan, PhD, is a molecular biologist, UC San Francisco professor, and director of the intensely interdisciplinary Quantitative Biosciences Institute (QBI) under the UCSF School of Pharmacy. He is also a senior investigator at the Gladstone Institutes.
He led the work to create the SARS-CoV-2 interactome and assembled the QBI Coronavirus Research Group (QCRG), which includes hundreds of scientists from around the world. His research focuses on developing and using unbiased, quantitative systems approaches to study a wide variety of diseases with the ultimate goal of developing new therapeutics.
Nevan serves as Director of The HARC Center, an NIH-funded collaborative group that focuses on the structural characterization of HIV-human protein complexes. Dr. Krogan is also the co-Director of three Cell Mapping initiatives, the Cancer Cell Mapping Initiative (CCMI), the Host Pathogen Map Initiative (HPMI) and the Psychiatric Cell Map Initiative (PCMI). These initiatives map the gene and protein networks in healthy and diseased cells with these maps being used to better understand disease and provide novel therapies to fight them.
He has authored over 250 papers in the fields of genetics and molecular biology and has given over 250 lectures and seminars around the world. He is a Searle Scholar, a Keck Distinguished Scholar and was recently awarded the Roddenberry Prize for Biomedical Research.